Novo Nordisk Presents Data on Semaglutide and Obesity Pipeline Therapies at EASD Congress

Novo Nordisk will present new data on semaglutide at the EASD diabetes congress, including its impact on reducing 'food noise' and body composition, as well as cardiovascular benefits. The company will also showcase data on its obesity pipeline, including cagrilintide and amycretin. The first head-to-head real-world study, REACH, shows superiority of Ozempic over dulaglutide on cardiovascular events.